September 15, 2025
Bayer is urging the Ninth Circuit not to grant a new trial over claims that it locked up the market for pet flea and tick treatment, saying the only evidence that rival Tevra showed a jury at trial was "highly dubious."
July 14, 2025
Tevra Brands LLC called on the Ninth Circuit to order a new trial after it said a lower court made several errors that prevented it from showing a jury that Bayer HealthCare LLC used exclusive contracts to lock up the market for a flea and tick treatment for dogs and cats.
January 22, 2025
A California federal judge refused to give Tevra Brands LLC a do-over on allegations that Bayer used exclusive contracts to anticompetitively lock up the market for flea and tick treatments for dogs, finding the veterinary drugmaker was just rehashing previously rejected arguments attacking a key expert witness.
August 01, 2024
A California federal jury on Thursday cleared Bayer of allegations that it owes millions for cutting anticompetitive deals with pet product retailers to undermine competition from generics makers of flea and tick treatments for dogs.
July 22, 2024
Tevra Brands LLC told a California federal jury during antitrust trial openings Monday that Bayer owes millions of dollars for allegedly cutting anticompetitive deals with retailers to undermine competition from anti-flea-and-tick treatment generics, while Bayer defended its "reasonable" and optional retailer discounts and criticized Tevra's "astronomical" damages demand.
May 01, 2024
A California federal judge has largely declined Bayer's bid to dismiss generics competitor Tevra's pet medication antitrust suit, saying in an order released Wednesday that there are factual disputes about whether Bayer's exclusivity deals with distributors and retailers significantly foreclosed Tevra's potential sales in the market.
May 03, 2021
Bayer HealthCare LLC and a former subsidiary are seeking to escape pet medication company Tevra Brands LLC's $114 million antitrust suit for flea and tick treatment products, arguing that Tevra's proposed market argument is "fatally flawed because it fails to include all reasonably interchangeable products."
July 30, 2020
A California federal judge expressed "a lot of concerns" Thursday about the adequacy of Tevra Brands LLC's $114 million pet medication antitrust complaint against Bayer, saying she's hesitant to "open up the floodgates of what will be enormously expensive discovery."
June 23, 2020
A California federal judge overseeing a $114 million antitrust case against U.S.-based Bayer HealthCare LLC ruled Tuesday that the COVID-19 pandemic isn't enough reason to allow the generic pet medication company that brought the suit to serve Bayer's German parent company via email.
June 01, 2020
Bayer HealthCare urged a California federal court against allowing a generic pet medication maker to flout international protocol for how to serve documents in a $114 million antitrust case, saying the company is trying to use the COVID-19 pandemic as a scapegoat for its own delays and errors.